KaloBios Pharmaceuticals(KBIO)- NASDAQ
  • Mon, Aug. 29, 10:26 AM
    • In a statement, KaloBios Pharmaceuticals (KBIO +7.1%) says former CEO Martin Shkreli has sold his entire stake in the firm to other investors in private transactions.
    • The company continues its turnaround efforts. It emerged from Chapter 11 bankruptcy on June 30 with $14M in equity financing and the rights to develop antiparasitic drug benznidazole for Chagas disease. A Phase 1 study of product candidate lenzilumab in chronic myelomonocytic leukemia is underway as well.
    | Mon, Aug. 29, 10:26 AM | 2 Comments
  • Fri, Aug. 19, 12:51 PM
    | Fri, Aug. 19, 12:51 PM
  • Fri, Aug. 19, 11:03 AM
    | Fri, Aug. 19, 11:03 AM | 3 Comments
  • Wed, Jan. 13, 6:56 AM
    • The new directors at KaloBios Pharmaceuticals (NASDAQ:KBIO) have decided to withdraw the company's Nasdaq appeal, opting instead to focus the firm's resources on executing its business plan and reorganization. Accordingly, the stock will be delisted today. Shares will be eligible to trade in over-the-counter markets.
    • Previously: Nasdaq clarifies bases for KaloBios delisting (Dec. 31, 2015)
    • Previously: KaloBios files delisting appeal, hearing set for February 25 (Dec. 29, 2015)
    • Update: Shares are changing hands over-the-counter at ~$2, down 92% from $25, the price level when halted by Nasdaq on December 17.
    | Wed, Jan. 13, 6:56 AM
  • Mon, Jan. 11, 1:49 PM
    • KaloBios Pharmaceuticals (NASDAQ:KBIO) announces the election of two independent directors to the board: Ronald Barliant and Dr. Cameron Durrant. Also, board member Michael Harrison resigned effective January 7.
    • Dr. Durrant, who will serve as Chairman, is a seasoned pharma/biotech executive and turnaround specialist.
    • Mr. Barliant is an attorney and former bankruptcy judge for the Northern District of  Illinois.
    | Mon, Jan. 11, 1:49 PM
  • Thu, Jan. 7, 3:30 PM
    • Embattled former Turing Pharmaceuticals and KaloBios (NASDAQ:KBIO) chief Martin Shkreli has put his $45M E*Trade account up in order to post his $5M bail after being arrested on fraud charges. At least he gets to keep his $2M Wu-Tang Clan album (for now).
    | Thu, Jan. 7, 3:30 PM | 2 Comments
  • Dec. 31, 2015, 11:23 AM
    • In a letter to KaloBios Pharmaceuticals (NASDAQ:KBIO), Nasdaq notifies the company that its Chapter 11 bankruptcy filing is a separate and additional basis for delisting, as is the resignation of two board members, Tom Fernandez and Marek Biestek, which leaves only one member on its audit committee.
    • The company's delisting appeal and the additional bases will be discussed at the hearing on February 25.
    • Previously: KaloBios files delisting appeal, hearing set for February 25 (Dec. 29)
    | Dec. 31, 2015, 11:23 AM | 7 Comments
  • Dec. 30, 2015, 4:25 AM
    • KaloBios Pharmaceuticals (NASDAQ:KBIO), the biotechnology company formerly led by Martin Shkreli, has filed for Chapter 11 bankruptcy, listing both its assets and liabilities in the range of $1M-$10M.
    • The move comes on the heels of KaloBios' appeal of the Nasdaq decision to delist its shares, as well as the firm's failure to file a quarterly financial report.
    • Previously: KaloBios files delisting appeal, hearing set for February 25 (Dec. 29 2015)
    | Dec. 30, 2015, 4:25 AM | 18 Comments
  • Dec. 29, 2015, 12:56 PM
    • KaloBios (NASDAQ:KBIO) ain't dead yet. It filed an appeal with Nasdaq over its delisting, originally planned for December 30. A hearing is scheduled for February 25. In the meantime, the company will retain its listing, although trading has yet to resume from its December 17 suspension.
    | Dec. 29, 2015, 12:56 PM | 12 Comments
  • Dec. 28, 2015, 9:15 AM
    | Dec. 28, 2015, 9:15 AM | 4 Comments
  • Dec. 24, 2015, 10:12 AM
    • The end is nigh for KaloBios Pharmaceuticals (NASDAQ:KBIO). The Nasdaq has notified the company that it intends to delist it on December 30 due to the criminal indictment and arrest of former CEO Martin Shkreli, the arrest and indictment of former outside counsel Evan Greebel and a civil complaint by the SEC against both men.
    • The company has until December 28 to request an appeal.
    • In November, unlucky investors caught on the wrong side experienced one of the most brutal short squeezes in history after an investor group led by Mr. Shkreli bought most of the stock in the defunct company. Shares rocketed from a low of $0.44 on November 16 to a high of $45.82 on November 23.
    • Trading has yet to resume after being suspended on December 17.
    • Previously: KaloBios CFO, accountants resign; facing Dec. 30 delisting (Dec. 23)
    | Dec. 24, 2015, 10:12 AM | 13 Comments
  • Dec. 23, 2015, 4:10 PM
    • KaloBios Pharmaceuticals (NASDAQ:KBIO) -- the company that ousted chief Martin Shkreli after his arrest on securities fraud charges -- says in an 8-K that its interim CFO and accounting firm have resigned, and that Nasdaq could delist the shares by Dec. 30.
    • Christopher Thorn, the company's interim chief financial officer, submitted a resignation on Monday, KaloBios says. The same day, Marcum LLP resigned as the company's independent registered public accounting firm.
    • Nasdaq staff notified the company that it intended to delist the stock for a number of reasons under its rule 5101, including the criminal indictment and arrest of Shkreli, and the arrest and indictment of the company's former outside counsel, Evan Greebel.
    • The company also hasn't filed its 10-Q for the period ended Sept. 30. If KaloBios doesn't appeal Nasdaq's determination, the common stock will be delisted at the opening of business on Dec. 30.
    • Previously: Turing Pharma restructures, cuts workforce (Dec. 22 2015)
    • Previously: Shkreli out at KaloBios (Dec. 21 2015)
    • Previously: KaloBios chief Shkreli arrested on securities fraud charge; shares plunge 50% premarket (Dec. 17 2015)
    | Dec. 23, 2015, 4:10 PM | 13 Comments
  • Dec. 22, 2015, 9:36 PM
    • Privately held Turing Pharmaceuticals AG interim CEO Ron Tilles isn't wasting any time making his presence felt after the departure of former CEO Martin Shkreli. With the aim of reducing costs and realigning its business priorities, the company has streamlined its operations, including a reduction in headcount.
    • A search for a permanent CEO is underway. The company also intends to expand its board to include new independent members.
    • Previously: Turing board close to replacing Shkreli (Dec. 18)
    • Previously: Martin Shkreli calls fraud charges 'baseless' (Dec. 20)
    • Related ticker: (NASDAQ:KBIO)
    | Dec. 22, 2015, 9:36 PM | 5 Comments
  • Dec. 21, 2015, 9:42 AM
    | Dec. 21, 2015, 9:42 AM | 8 Comments
  • Dec. 17, 2015, 7:12 AM
    • According to the Feds, biotech bad boy Martin Shkreli really is. He was apparently arrested this morning in a securities fraud investigation related to his tenure at Retrophin. He is accused to illegally taking company stock to pay off debts from unrelated business dealings.
    • In August, Retrophin sued Mr. Shkreli for $65M for allegedly paying off underwater investors in hedge funds he controlled with 590K shares of company stock and over $2.7M in company cash.
    • He earned his notoriety when he raised the list price of the toxoplasmosis drug Daraprim from $13.50 per pill to $750 after acquiring the rights to the 62 year-old drug from Impax Laboratories. Beforehand, Daraprim's market price was ~$1 per pill.
    • KaloBios (NASDAQ:KBIO), a bankrupt company a group of investors led by Mr. Shkreli resuscitated from the ashes, is down 50% premarket on increased volume.
    • Previously: Retrophin sues former chief Shkreli for $65M (Aug. 18)
    • Update: trading in KBIO remains on hold as of 12:49 pm ET, six hours after the halt was initiated under code T12, signifying that trading will be suspended until Nasdaq receives certain additional information.
    | Dec. 17, 2015, 7:12 AM | 20 Comments
  • Dec. 15, 2015, 12:48 PM
    | Dec. 15, 2015, 12:48 PM